Eli Lilly has filed lawsuits against six entities accused of selling black market versions of its experimental weight-loss drug retatrutide, a GLP-1 medication that has not yet received regulatory approval. The lawsuits target U.S.-based compounding pharmacies, medical spas and online sellers allegedly marketing the unapproved drug as a weight-loss "hack" while falsely claiming their products are for "research-use only."

Retatrutide is part of a class of drugs that includes FDA-approved medications like Ozempic and Mounjaro, which have seen explosive demand for weight loss purposes. Eli Lilly's legal action reflects broader concerns about the proliferation of unlicensed versions of these high-demand treatments in an unregulated marketplace.

What the Right Is Saying

Conservative critics of pharmaceutical industry litigation argue that such lawsuits can restrict patient access to treatments. Some Republican lawmakers have questioned whether large pharmaceutical companies use legal action to maintain monopolies and keep drug prices elevated.

The Institute for Justice, a libertarian law firm that often challenges corporate litigation, has argued that compounding pharmacies serve important functions in providing customized medications when FDA-approved options are unavailable or unaffordable. Critics note that GLP-1 drugs like Ozempic can cost over $900 per month without insurance coverage.

Some conservative commentators have suggested that the high demand for weight-loss medications — and the resulting black market — reflects a failure of the regulatory system to approve treatments quickly enough to meet consumer needs. They argue that faster approval processes would reduce incentives for patients to seek unregulated alternatives.

What the Left Is Saying

Democratic lawmakers and consumer advocacy groups largely support pharmaceutical companies' efforts to combat counterfeit drugs. They argue that protecting FDA approval processes is essential for patient safety, noting that unapproved medications bypass critical quality controls and safety reviews.

Senator Dick Durbin of Illinois said protecting the integrity of the drug approval process "protects patients from potentially dangerous products." Public health advocates at organizations such as the Pew Charitable Trusts have noted that compounded drugs, while serving legitimate needs in some cases, can expose patients to risks when they contain unverified ingredients or improper dosages.

Consumer Reports has argued that patients seeking weight-loss treatments should have access to medications that have undergone rigorous clinical trials and received regulatory approval, rather than relying on unregulated alternatives of uncertain quality.

What the Numbers Show

Eli Lilly's retatrutide remains in clinical trials and has not received FDA approval. The drug is one of several experimental GLP-1 medications being developed by multiple pharmaceutical companies for weight-loss indications.

The global market for GLP-1 drugs reached approximately $40 billion in 2024, according to estimates from analysts at Morgan Stanley. Demand has consistently outstripped supply since the class of drugs gained widespread attention for weight-loss effects, creating conditions that industry observers say encourage black market activity.

Compounded versions of FDA-approved GLP-1 medications have grown significantly, with the FDA reporting a substantial increase in adverse events associated with compounded semaglutide products. Eli Lilly has previously taken legal action against wellness clinics and pharmacies selling unauthorized versions of its approved drug Mounjaro.

The Bottom Line

Eli Lilly's lawsuits highlight ongoing tensions between pharmaceutical companies seeking to protect their intellectual property and market access, and patients facing high costs or limited availability of FDA-approved medications. Retatrutide, if approved, could compete in the lucrative weight-loss drug market estimated to reach $100 billion annually by the end of the decade.

The cases will likely test legal boundaries around compounding pharmacy practices and what constitutes permissible "research-use" labeling. Consumer advocates on both sides are watching to see whether courts distinguish between legitimate compounding for patients with specific medical needs versus mass production of unapproved drug alternatives.

Patients seeking weight-loss treatments should consult healthcare providers about FDA-approved options, as unapproved medications may lack verified safety profiles and consistent dosing.